{"organizations": [], "uuid": "91239c1e0d278af110ca2ea5ee7184aded0b5576", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180308.html", "section_title": "Archive News &amp; Video for Thursday, 08 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-onconova-therapeutics-reports-full/brief-onconova-therapeutics-reports-full-year-2017-results-idUSASB0C9EE", "country": "US", "domain_rank": 408, "title": "BRIEF-Onconova Therapeutics Reports Full-Year 2017 Results", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.152, "site_type": "news", "published": "2018-03-08T20:21:00.000+02:00", "replies_count": 0, "uuid": "91239c1e0d278af110ca2ea5ee7184aded0b5576"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-onconova-therapeutics-reports-full/brief-onconova-therapeutics-reports-full-year-2017-results-idUSASB0C9EE", "ord_in_thread": 0, "title": "BRIEF-Onconova Therapeutics Reports Full-Year 2017 Results", "locations": [], "entities": {"persons": [{"name": "highli", "sentiment": "neutral"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "onconova therapeutics inc", "sentiment": "negative"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 8 (Reuters) - Onconova Therapeutics Inc:\n* ONCONOVA THERAPEUTICS, INC. REPORTS BUSINESS HIGHLIGHTS AND FULL YEAR 2017 FINANCIAL RESULTS\n* ONCONOVA THERAPEUTICS INC - CASH AND CASH EQUIVALENTS AS OF DECEMBER 31, 2017, TOTALED $4.0 MILLION, COMPARED TO $21.4 MILLION AS OF DECEMBER 31, 2016\n* ONCONOVA THERAPEUTICS - EXPECTS CASH AND CASH EQUIVALENTS WILL BE SUFFICIENT TO FUND ONGOING TRIALS AND OPERATIONS INTO Q3 2018 Source text for Eikon: Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-08T20:21:00.000+02:00", "crawled": "2018-03-09T14:25:43.035+02:00", "highlightTitle": ""}